GlassScriptPhysician profile
Cheryll G Udani
NPI 1548604713
$307.15
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $150 · 2020: $138 · 2021: $19.20.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.92 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $49.62 | 2019-2020 | |
| Amgen INC. | $33.23 | 2020 | |
| Depuy Synthes Sales INC. | $24.85 | 2020 | |
| Abbvie INC. | $19.20 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $16.82 | 2019 | |
| Pfizer INC. | $16.54 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $14.78 | 2020 | |
| Optinose US, INC. | $14.26 | 2020 | |
| Merck Sharp & Dohme LLC | $14.14 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $13.88 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.52 | 2019 | |
| Allergan, INC. | $12.39 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cheryll Udani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.